Stream Bio, 2BScientific Launch New Bioimaging Probes

On Sept. 19, 2018, Stream Bio, a developer and manufacturer of bioimaging molecular probes, and 2BScientific, a life sciences distributor, launched Conjugated Polymer Nanoparticle (CPN) products, new bioimaging probes.

The CPN products can be used in molecular imaging and R&D applications, such as flow cytometry, enzyme-linked immunosorbent assay, fluorescent in situ hybridization, western blotting fluorescence resonance energy transfer, intensity-hue-saturation, and lateral flow assays. The probes are available in four emission wavelengths from 475 nm to 680 nm, covering the colors blue, green, yellow, and red.

Current bioimaging products have weak fluorescence and low sensitivities, which often fade prematurely, according to Stream Bio. The CPNs provide significant photostability and sensitivity (brightness) with highly specific targeting and magnetic cell-purification capability, while remaining compliant with existing lab protocols, the company reports.

Although the CPNs are initially aimed at in-vitro R&D, the company anticipates that the rollout of the technology will also positively impact in-vivo R&D, diagnostics, and therapeutics in the future.

“The CPNs have an enormous potential to transform the sensitivity and performance of a multitude of pharmacology and in-vitro biological assays and experimental systems. It is amazing to be part of the team bringing this exciting technology to the market and giving researchers across the life science and healthcare field access to the enhanced performance offered by the CPN,” said Dermott O’Callaghan, head of product development at Stream Bio, in a company press release.

“We are very excited for our first launch and look forward to extending this into a number of other [European Union] countries in the near future and ultimately worldwide. We are planning on a rapid expansion of the range over the coming 12 months, extending their utility into a number of new applications and widening their use in our key areas,” said Steve Self, commercial director at Stream Bio, in the press release.

“The agreement with Stream Bio means we are now offering a novel range of products and solutions to the UK and Ireland R&D community. We are very proud to partner with such an innovative company and believe that the technology developed by Steam Bio shows excellent potential. We look forward to providing them our customers, particularly those using flow cytometry and microscopy to study disease,” added James Bernard, CEO of 2BScientific, in the press release.

Source: Stream Bio